Oss, The Netherlands, Erlangen, Germany September 18, 2019 —http://www.citryll.com/ announced today that it has established a collaboration with Dr. Markus Hoffmann of the Department of Medicine 3, Friedrich Alexander University of Erlangen-Nürnberg to investigate the mechanism of action (MoA) of its lead CIT-013 (tACPA) antibody programme.CIT-013 interferes with the formation, function and clearance of neutrophil… Read More


Citryll’s CIT-013 could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis and organ damage due to sepsis Lonza’sin silicopreclinical services used to assess manufacturability and immunogenicity Lonza to supply final drug product in finished format for Citryll’s clinical studies Oss, The Netherlands and Basel, Switzerland, 9 September 2019– The Netherlands-based… Read More


Oss, The Netherlands, July 3, 2019 —hannounced today the first closing of a targeted € 15 million investment round, funded by ModiQuest B.V., BOM Brabant Ventures, BrightGene, and Curie Capital. The proceeds will be used to progress the pre-clinical and clinical development of Citryll’s tACPA antibodies, inhibitors of neutrophil extracellular traps (NETs) and their formation (NETosis).… Read More


Renato Chirivi, Ph.D. Head Internal Therapeutic development and Helmuth van Es, Ph.D. CEO of Citryll will be attending the annual meeting of the American College for Rheumatology in San Francisco. The conference will be held from 8-11 November at the Moscone Center in San Francisco. We will be presenting the tACPA programme and its NETosis… Read More